S0417 A Phase II Study of Bortezomib (Velcade™, PS-341), Thalidomide, and Dexamethasone in Patients With Refractory Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 18 Apr 2013
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 06 Jun 2012 Actual patient number is 7 according to ClinicalTrials.gov.
- 06 Jun 2012 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 06 Jun 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.